Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)

Andrea Ardizzoni; Paolo Pronzato; Lazzaro Repetto; Mario De Palma; Luciano Canobbio; Marcella Gulisano; Vittorio Fusco; Riccardo Rosso; Franco Ganzina

doi:10.3109/07357908809080069

Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)

Andrea Ardizzoni, Paolo Pronzato, Lazzaro Repetto, Mario De Palma, Luciano Canobbio, Marcella Gulisano, Vittorio Fusco, Riccardo Rosso, Franco Ganzina

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m² for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.

Original language	English
Pages (from-to)	409-411
Number of pages	3
Journal	Cancer Investigation
Volume	6
Issue number	4
DOIs	https://doi.org/10.3109/07357908809080069
Publication status	Published - 1988

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.3109/07357908809080069

Fingerprint Dive into the research topics of 'Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this

Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC). / Ardizzoni, Andrea; Pronzato, Paolo; Repetto, Lazzaro; De Palma, Mario; Canobbio, Luciano; Gulisano, Marcella; Fusco, Vittorio; Rosso, Riccardo; Ganzina, Franco.

In: Cancer Investigation, Vol. 6, No. 4, 1988, p. 409-411.

Research output: Contribution to journal › Article › peer-review

@article{29984aa5ec144607870d089737a1bef7,

title = "Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)",

abstract = "The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.",

author = "Andrea Ardizzoni and Paolo Pronzato and Lazzaro Repetto and {De Palma}, Mario and Luciano Canobbio and Marcella Gulisano and Vittorio Fusco and Riccardo Rosso and Franco Ganzina",

year = "1988",

doi = "10.3109/07357908809080069",

language = "English",

volume = "6",

pages = "409--411",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)

AU - Ardizzoni, Andrea

AU - Pronzato, Paolo

AU - Repetto, Lazzaro

AU - De Palma, Mario

AU - Canobbio, Luciano

AU - Gulisano, Marcella

AU - Fusco, Vittorio

AU - Rosso, Riccardo

AU - Ganzina, Franco

PY - 1988

Y1 - 1988

N2 - The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.

AB - The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.

UR - http://www.scopus.com/inward/record.url?scp=0023775271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023775271&partnerID=8YFLogxK

U2 - 10.3109/07357908809080069

DO - 10.3109/07357908809080069

M3 - Article

C2 - 2846128

AN - SCOPUS:0023775271

VL - 6

SP - 409

EP - 411

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -

Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this